Yu Zhi-Hai, Wang Hai-Tao, Tu Can
Department of Interventional, The Affiliated Hospital of School of Medicine of Ningbo University, No. 247 Renmin Road, Jiangbei District, Ningbo, 315020, Zhejiang Province, People's Republic of China.
Eur J Med Res. 2017 Jan 5;22(1):2. doi: 10.1186/s40001-016-0240-y.
This study was conducted to explore the diagnostic value of microRNA-143 (miRNA-143) in predicting in-stent restenosis (ISR) of lower extremity arterial occlusive disease (LEAOD).
From February 2012 to March 2015, 165 patients (112 males and 53 females) with LEAOD undergoing interventional treatment were enrolled in this study. Serum miRNA-143 expression was detected using quantitative real-time polymerase chain reaction (qRT-PCR). Patients were assigned into the restenosis and non-restenosis groups according to routine surveillance postoperative angiography. A logistic regression analysis was conducted to analyze the risk factors for ISR in LEAOD patients. A receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of miRNA-143 in predicting ISR for LEAOD patients.
There were 74 and 91 patients in the restenosis and non-restenosis groups, respectively. Before the treatment, there were significant differences in history of diabetes, smoking status, blood sugar level (BSL) at admission, low-density lipoprotein cholesterol (LDL-C) level, and stent diameter between the restenosis and non-restenosis groups (all P < 0.05). Serum miRNA-143 expression was lower in the restenosis group than in the non-restenosis group (P < 0.05). Serum miRNA-143 expression in the restenosis group was correlated with smoking status, history of diabetes, BSL, and LDL-C (all P < 0.05). Logistic regression analysis demonstrated that miRNA-143, LDL-C, and smoking status were correlated with the postoperative ISR (all P < 0.05). ROC curve analysis revealed that the area under the curve (AUC) of miRNA-143 in predicting ISR for LEAOD patients was 0.866.
Our results indicate that miRNA-143 can be a promising tool for predicting the ISR in LEAOD patients.
本研究旨在探讨微小RNA-143（miRNA-143）在预测下肢动脉闭塞性疾病（LEAOD）支架内再狭窄（ISR）方面的诊断价值。
2012年2月至2015年3月，本研究纳入了165例行介入治疗的LEAOD患者（男性112例，女性53例）。采用定量实时聚合酶链反应（qRT-PCR）检测血清miRNA-143表达。根据术后常规血管造影将患者分为再狭窄组和无再狭窄组。进行逻辑回归分析以分析LEAOD患者ISR的危险因素。绘制受试者工作特征（ROC）曲线以评估miRNA-143对LEAOD患者ISR的诊断价值。
再狭窄组和无再狭窄组分别有74例和91例患者。治疗前，再狭窄组和无再狭窄组在糖尿病史、吸烟状况、入院时血糖水平（BSL）、低密度脂蛋白胆固醇（LDL-C）水平和支架直径方面存在显著差异（均P<0.05）。再狭窄组血清miRNA-143表达低于无再狭窄组（P<0.05）。再狭窄组血清miRNA-143表达与吸烟状况、糖尿病史、BSL和LDL-C相关（均P<0.05）。逻辑回归分析表明，miRNA-143、LDL-C和吸烟状况与术后ISR相关（均P<0.05）。ROC曲线分析显示，miRNA-143预测LEAOD患者ISR的曲线下面积（AUC）为0.866。
我们的结果表明，miRNA-143可能是预测LEAOD患者ISR的一种有前景的工具。
